Read by QxMD icon Read

Clinical & Translational Oncology

M Bonet, T Bonfill, M Nuñez, L De Verdonces, E Mur, E Gallardo, L Fernandez-Morales, A Aguilar, J Prats, M Arenas
In the original version of this article the figure captions of Figs. 1 and 2 were interchanged.
March 15, 2018: Clinical & Translational Oncology
C Yuan, Q Wang
PURPOSE: The aim of this study was to determine whether different radiotherapy (RT) fractionation schemes induce disparate effects on lymphocyte and its subsets in breast cancer patients. METHODS: 60 female patients diagnosed with breast cancer were recruited in this study after receiving modified radical mastectomy and were randomly divided into two groups. One group received irradiation at a standard dose of 50 Gy in 25 fractions and the other at a dose of 40...
March 13, 2018: Clinical & Translational Oncology
J Hou, W Jiang, L Zhu, S Zhong, H Zhang, J Li, S Zhou, S Yang, Y He, D Wang, X Chen, F Deng, Q Zhang, J Wang, J Hu, W Zhang, L Ding, J Zhao, J Tang
Circular RNAs (CircRNAs) are a type of non-coding RNAs (NcRNAs) with a closed annular structure. Until next-generation sequencing (NGS) is developed, the misunderstanding of circRNAs 'splicing error' has changed, and the mysterious veil of circRNAs has been revealed. NGS provides an approach to investigate circRNAs. Many scholars point out that circRNAs may play an important role in many diseases, especially cancer. At the same time, exosomes, as a kind of extracellular vesicles loaded with many contents, are a hotspot in recent years...
March 13, 2018: Clinical & Translational Oncology
R Clèries, A Ameijide, M Buxó, J M Martínez, R Marcos-Gragera, M-L Vilardell, M Carulla, Y Yasui, M Vilardell, J A Espinàs, J M Borràs, J Galceran, À Izquierdo
BACKGROUND: We provide population-based long-term survival indicators of breast cancer patients by quantifying the observed survival, and the probabilities of death due to breast cancer and to other causes by age and tumor stage at diagnosis. METHODS: We included a total of 10,195 female patients diagnosed before 85 years with invasive primary breast cancer in Girona and Tarragona during the periods 1985-1994 and 1995-2004 and followed-up until December 31st 2014...
March 6, 2018: Clinical & Translational Oncology
M Durán-Poveda, P Jimenez-Fonseca, M Sirvent-Ochando, P P García-Luna, J L Pereira-Cunill, B Lema-Marqués, M T Parejo-Arrondo, C Belda-Iniesta
INTRODUCTION: Malnutrition is a common complication in cancer patients and can negatively affect the outcome of treatments. This study aimed to reach a consensus on nutritional needs and optimize nutritional care in the management of cancer patients at a national level. METHODS: A qualitative, multicenter, two-round Delphi study involving 52 specialists with experience in nutritional support in cancer patients was conducted. RESULTS: Regarding the presence of malnutrition, 57...
March 2, 2018: Clinical & Translational Oncology
S K Kamarajah
INTRODUCTION: This study aimed to evaluate the impact of adjuvant radiotherapy in patients undergoing pancreaticoduodenectomy (PD) for ampullary adenocarcinoma. METHODS: Using the Surveillance, Epidemiology, and End Results, patients with non-metastatic ampullary adenocarcinoma between 2004 and 2013 were identified. Cancer-specific survival and overall survival were estimated using Kaplan-Meier and Cox regression to obtain adjusted hazard ratio of survival. RESULTS: In this study, 1106 patients with ampullary adenocarcinoma were identified, of which 27% received adjuvant radiotherapy and the remaining 73% (803/1106) patients did not receive any adjuvant radiotherapy...
March 1, 2018: Clinical & Translational Oncology
J Jiang, M He, X Hu, C Ni, L Yang
PURPOSE: Pulmonary benign metastasizing leiomyoma (PBML), a rare condition of smooth muscle tumor, originates from women with a history of uterine leiomyoma (LM). Numerous genetic studies of uterine LM have been reported; however, there are few cytogenetic and molecular descriptions of PBML. Therefore, molecular subtyping is necessary to understand the pathogenesis of metastasizing sites. METHODS: Driver gene exon-capture sequencing was performed on one patient's peripheral blood, paraffin samples from primary uterine LM, and lung metastasizing leiomyoma 8 years later...
February 26, 2018: Clinical & Translational Oncology
R Correa, J Gómez-Millán, M Lobato, A Fernández, R Ordoñez, C Castro, Y Lupiañez, J A Medina
Sarcomas are an infrequent and heterogeneous group of neoplasia. Surgery with or without associated radiotherapy (RT) is the basic treatment for this type of tumour. To increase the therapeutic ratio (the index between cytotoxic effects in tumours and normal tissue complications with a certain dose of radiation), new advances are being investigated to increase local and distant control and to decrease the morbidity of the treatment. The aim of this review was to analyse the different strategies, based on technology and biology, which are being investigated to increase the therapeutic ratio of this disease...
February 23, 2018: Clinical & Translational Oncology
I García-Escobar, C Beato-Zambrano, J Muñoz Langa, E Brozos Vázquez, B Obispo Portero, D Gutiérrez-Abad, A J Muñoz Martín
The association between venous thromboembolism (VTE) and cancer has been recognized for more than 100 years. Numerous studies have been performed to investigate strategies to decrease VTE incidence and to establish whether treating VTE impacts cancer progression and overall survival. Accordingly, it is important to understand the role of the hemostatic system in tumorigenesis and progression, as there is abundant evidence associating it with cell survival and proliferation, tumor angiogenesis, invasion, and dissemination, and metastasis formation...
February 22, 2018: Clinical & Translational Oncology
X Pan, T Lv, F Zhang, H Fan, H Liu, Y Song
BACKGROUND: The subgroup of young patients with non-small-cell lung cancer (NSCLC) is poorly understood. We retrospectively studied the clinical characteristics, gene mutations, and outcomes of patients with NSCLC (aged ≤ 40 years). RESULTS: Of the 7494 patients with lung cancer diagnosed from February 2001 to October 2016, 252 aged ≤ 40 years showed NSCLC. We divided their cases into non-squamous cell carcinoma and squamous cell carcinoma groups according to their histology results...
February 19, 2018: Clinical & Translational Oncology
E Soto-Perez-de-Celis, R Cordoba, R Gironés, T Karnakis, I Paredero, Y Chavarri-Guerra, A P Navarrete-Reyes, J A Avila-Funes
Population aging represents a worldwide challenge. In Ibero-America (Spain, Portugal, and the American countries in which the Spanish or Portuguese language are spoken), the number of older adults is growing, leading to an increase in aging-related diseases such as cancer. Older adults already account for half of all cancer cases in Ibero-America, and this proportion will continue to increase. Furthermore, Ibero-American healthcare systems are not adequately prepared to provide care for older adults with cancer, mainly due to a lack of resources and generalized paucity of geriatric training for healthcare providers...
February 12, 2018: Clinical & Translational Oncology
Y Bao, S Zhang, Y Guo, X Wei, Y Zhang, Y Yang, H Zhang, M Ma, W Yang
PURPOSE: Esophageal squamous cell carcinoma (ESCC) is one of the most common cancers worldwide, and its outcome is poor. The purpose of this study was to determine the association between JNK1 and vitamin D receptor (VDR) expression and the prognosis of ESCC. METHODS: Immunohistochemical staining was conducted on ESCC tissue microarrays (362 pairs of ESCC and normal esophagus tissues). The epithelial and stromal expression levels of c-jun NH2-terminal kinase 1 (JNK1) and VDR were scored and correlated with the ESCC characteristics...
February 8, 2018: Clinical & Translational Oncology
H Cui, S Yang, Y Jiang, C Li, Y Zhao, Y Shi, Y Hao, F Qian, B Tang, P Yu
PURPOSE: Presence of cancer stem cells (CSCs) contributes to tumor outgrowth, chemo-resistance and relapse in some cancers including colorectal carcinoma (CRC). The current characterization methods of CSCs in CRC only allows enrichment of CSCs but not their purification. Recent reports showed that ST6 beta-galactoside alpha-2,6-sialyltransferase 1 (ST6Gal-I) plays an essential role in protecting tumor cells against harsh environment like oxidative stress and nutrient deprivation. Therefore, whether ST6Gal-I may be highly expressed in CSCs or whether it may enhance resistance of tumor cells to chemotherapy deserves exploration...
February 8, 2018: Clinical & Translational Oncology
A Santaballa, X Matías-Guiu, A Redondo, N Carballo, M Gil, C Gómez, M Gorostidi, M Gutierrez, A Gónzalez-Martín
In the original version of this article Figure 1 was shown incorrectly. The correct Figure 1 is shown here.
February 7, 2018: Clinical & Translational Oncology
M Rodríguez-Balada, B Roig, M Melé, M Salvat, L Martorell, J Borràs, J Gumà
PURPOSE: Germline promoter hypermethylation of BRCA1 and BRCA2 genes is an alternative event of gene silencing that has not been widely investigated in hereditary breast and ovarian cancer (HBOC) syndrome. METHODS: We analyzed germline BRCA promoter hypermethylation in HBOC patients with and without BRCA mutations and control subjects, using a recently developed BRCA methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay. RESULTS: Neither the patients tested nor the control subjects showed germline hypermethylation of the BRCA1 and BRCA2 promoter regions analyzed...
February 5, 2018: Clinical & Translational Oncology
Z Liu, W Liu
PURPOSE: Identifying patients who are at risk of relapse is a key challenge of primary breast cancer. The current study investigates the utility of urinary DNA in breast cancer management and as a predictor of relapse. This work also compares the sensitivity of plasma DNA with urinary DNA. METHODS: Blood plasma and urine specimens were collected concurrently from 200 breast cancer patients receiving neoadjuvant chemotherapy. Comparison of both plasma and urinary DNA was performed at baseline to determine assay significance...
February 1, 2018: Clinical & Translational Oncology
S Santasusagna, I Moreno, A Navarro, C Muñoz, F Martinez, R Hernández, J J Castellano, M Monzo
PURPOSE: Increasing evidence shows that altered metabolism is a critical hallmark in colon cancer. There is a strong need to explore the molecular mechanisms underlying cancer metabolism. Whether the aberrant expression of microRNAs contributes to cancer metabolism is not fully understood. miR-328 is a putative potential target of SLC2A1, but the regulating mechanism between them remains unknown. We have examined whether miR-328 directly regulates SLC2A1/GLUT1 expression in colon cancer cells...
January 26, 2018: Clinical & Translational Oncology
J Garde-Noguera, P Martín Martorell, M De Julián, J Perez Altozano, C Salvador Coloma, J García Sánchez, A Insa Molla, M Martín, X Mielgo Rubio, S Marin Liébana, A Blasco Cordellat, S Blasco Molla, R Gironés, D Marquez Medina, F Aparisi, M C Bas Cerda, S Macia Escalante, A Sánchez, O Juan Vidal
BACKGROUND: Immunotherapy increases overall response rate (ORR) and overall survival (OS) in patients with non-small-cell lung cancer (NSCLC). Prognostic and predictive factors are a high need. PATIENTS AND METHODS: Retrospective review of NSCLC patients treated with nivolumab was performed. Analyzed variables included age, sex, stage, performance status (PS), location of metastases, presence of tumour-related symptoms and comorbidities, number of metastasis locations, previous chemotherapy, anti-angiogenic and radiotherapy treatments, and analytical data from the standard blood count and biochemistry...
January 24, 2018: Clinical & Translational Oncology
Xiaoyu Yang, Xiaochun Peng, Jiangrong Huang
PURPOSE: 6-phosphogluconate dehydrogenase (6PGD), a key enzyme of the oxidative pentose phosphate pathway, is involved in tumor growth and metabolism. Although high 6PGD activity has been shown to be associated with poor prognosis, its role and therapeutic value in breast cancer remain unknown. METHODS: The levels and roles of 6PGD were analyzed in breast cancer cells and their normal counterparts. The underlying mechanisms of 6PGD's roles are also analyzed. RESULTS: We found that 6PGD is aberrantly activated in breast cancer as shown by its increased transcriptional and translational levels as well as enzyme activity in breast cancer tissues and cell lines compared to normal counterparts...
January 16, 2018: Clinical & Translational Oncology
A Zygogianni, M Protopapa, A Kougioumtzopoulou, F Simopoulou, S Nikoloudi, V Kouloulias
GBM is one of the most common and aggressive brain tumors. Surgery and adjuvant chemoradiation have succeeded in providing a survival benefit. Although most patients will eventually experience local recurrence, the means to fight recurrence are limited and prognosis remains poor. In a disease where local control remains the major challenge, few trials have addressed the efficacy of local treatments, either surgery or radiation therapy. The present article reviews recent advances in the biology, imaging and biomarker science of GBM as well as the current treatment status of GBM, providing new perspectives to the problem of local recurrence...
January 15, 2018: Clinical & Translational Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"